Statistics

Serum-Derived Bovine Immunoglobulin/Protein Isolate Therapy for ...

www.weinstockibsdreprint.com/

Background: A small double-blind study showed benefits of serum-derived bovine immunoglobulin/protein isolate (SBI), for diarrhea-predominant irritable ...

Weinstockibsdreprint.com

Domain is redirected to: Scirp.org

Conversion Technology Metas Server

Weinstockibsdreprint.com is hosted in United States / Los Angeles . Weinstockibsdreprint.com doesn't use HTTPS protocol. Number of used technologies: 4. First technologies: CSS, Html, Javascript, Number of used javascripts: 5. First javascripts: Jquery.js, Order.js, Jquery-1.4.2.js, Number of used analytics tools: 1. First analytics tools: Google Analytics, Its server type is: Sun-ONE-Web-Server/6.1.

Technologies in use by Weinstockibsdreprint.com

Technology

Number of occurences: 4

CSS
Html
Javascript
jQuery

Javascripts

Number of occurences: 5

jquery.js
Order.js
jquery-1.4.2.js
jquery.funkyUI.js
jquery1.4.4.js

Analytics

Number of occurences: 1

Google Analytics

Server Type

Sun-ONE-Web-Server/6.1

Powered by

ASP.NET

Social

Number of occurences: 1

Add This

Conversion rate optimization
Clickable call number	Not founded!
Conversion form (contact form, subcriber)	Founded!
Clickable email	Not founded!
CTA (call to action) button	Not founded!
List	Founded!
Image	Not founded!
Enhancement	Not founded!
Responsive website	Founded!
Facebook sharing	Not founded!
Google+ sharing	Not founded!
Twitter sharing	Not founded!
Linkedin sharing	Not founded!
Blog on the webiste	Not founded!

HTTPS (SSL) - Weinstockibsdreprint.com

Missing HTTPS protocol.

Meta - Weinstockibsdreprint.com

Number of occurences: 43

Name:
Content: Yes
Name: robots
Content: all
Name: MSSmartTagsPreventParsing
Content: True
Name: title
Content: Serum-Derived Bovine Immunoglobulin/Protein Isolate Therapy for Patients with Refractory Irritable Bowel Syndrome
Name: keywords
Content: Irritable Bowel Syndrome (IBS),Small Intestinal Bacterial Overgrowth (SIBO),Serum-Derived Bovine Immunoglobulin/Protein Isolate (SBI)
Name: description
Content: Background: A small double-blind study showed benefits of serum-derived bovine immunoglobulin/protein isolate (SBI), for diarrhea-predominant irritable bowel syndrome (IBS-D) [1]. The purpose of this chart review was to assess safety and clinical outcomes of SBI in refractory irritable bowel syndrome (IBS) patients. Methods: A retrospective review of 35 IBS patients with diarrhea or mixed diarrhea/constipation pattern (IBS-M) who were administered SBI 5 grams twice daily was performed. Clinical response (â€œgood responseâ€ or â€œno responseâ€) and adverse events were determined by follow-up after four weeks of therapy. Patients were included for evaluation if a lactulose breath test (LBT) had been performed prior to SBI. All patients were refractory to common IBS therapies. The response rate to the inclusion of SBI was calculated in three separate groups: dividing patients based on their LBT results (positive or negative), dividing patients by their IBS diagnosis (IBS-D or IBS-M) and grouping all patients together. Results: Analysis was carried out on 26 IBS-D/-M patients with LBT results. Two patients were lost to follow-up and were excluded from data analysis. The positive LBT group (N = 11) had a 73% (p = 0.117) positive response rate to SBI. The negative LBT group (N = 13) had a significant response rate of 77% (p = 0.040). If patients were divided by IBS diagnosis or grouped together, the response rate to SBI was similarly ranging from 69% - 88%. Adverse events leading to cessation of SBI occurred in 3 of 24 patients. Conclusion: SBI appeared to be a safe and effective nutritional moiety in refractory IBS-D and IBS-M patients. Larger, double-blind studies are needed.
Name: citation_journal_title
Content: Open Journal of Gastroenterology
Name: citation_publisher
Content: Scientific Research Publishing
Name: citation_authors
Content: Leonard B. Weinstock;Victoria S. Jasion
Name: citation_title
Content: Serum-Derived Bovine Immunoglobulin/Protein Isolate Therapy for Patients with Refractory Irritable Bowel Syndrome
Name: citation_volume
Content: 04
Name: citation_date
Content: 2014-10-16
Name: citation_year
Content: 2014
Name: citation_doi
Content: 10.4236/ojgas.2014.410047
Name: citation_issnPrint
Content: 2163-9450
Name: citation_issnOnline
Content: 2163-9469
Name: citation_abstract
Content: Background: A small double-blind study showed benefits of serum-derived bovine immunoglobulin/protein isolate (SBI), for diarrhea-predominant irritable bowel syndrome (IBS-D) [1]. The purpose of this chart review was to assess safety and clinical outcomes of SBI in refractory irritable bowel syndrome (IBS) patients. Methods: A retrospective review of 35 IBS patients with diarrhea or mixed diarrhea/constipation pattern (IBS-M) who were administered SBI 5 grams twice daily was performed. Clinical response (â€œgood responseâ€ or â€œno responseâ€) and adverse events were determined by follow-up after four weeks of therapy. Patients were included for evaluation if a lactulose breath test (LBT) had been performed prior to SBI. All patients were refractory to common IBS therapies. The response rate to the inclusion of SBI was calculated in three separate groups: dividing patients based on their LBT results (positive or negative), dividing patients by their IBS diagnosis (IBS-D or IBS-M) and grouping all patients together. Results: Analysis was carried out on 26 IBS-D/-M patients with LBT results. Two patients were lost to follow-up and were excluded from data analysis. The positive LBT group (N = 11) had a 73% (p = 0.117) positive response rate to SBI. The negative LBT group (N = 13) had a significant response rate of 77% (p = 0.040). If patients were divided by IBS diagnosis or grouped together, the response rate to SBI was similarly ranging from 69% - 88%. Adverse events leading to cessation of SBI occurred in 3 of 24 patients. Conclusion: SBI appeared to be a safe and effective nutritional moiety in refractory IBS-D and IBS-M patients. Larger, double-blind studies are needed.
Name: citation_fulltext_html_url
Content: 2-1900251_50770.htm
Name: citation_pdf_url
Content: http://www.scirp.org/journal/PaperDownload.aspx?paperID=50770
Name: citation_abstract_html_url
Content: http://www.scirp.org/journal/PaperInformation.aspx?PaperID=50770&#abstract
Name: dc.title
Content: Serum-Derived Bovine Immunoglobulin/Protein Isolate Therapy for Patients with Refractory Irritable Bowel Syndrome
Name: dc.creator
Content: Victoria S. Jasion
Name: dcterms.issued
Content: 2014-10-16
Name: dc.description
Content: Background: A small double-blind study showed benefits of serum-derived bovine immunoglobulin/protein isolate (SBI), for diarrhea-predominant irritable bowel syndrome (IBS-D) [1]. The purpose of this chart review was to assess safety and clinical outcomes of SBI in refractory irritable bowel syndrome (IBS) patients. Methods: A retrospective review of 35 IBS patients with diarrhea or mixed diarrhea/constipation pattern (IBS-M) who were administered SBI 5 grams twice daily was performed. Clinical response (â€œgood responseâ€ or â€œno responseâ€) and adverse events were determined by follow-up after four weeks of therapy. Patients were included for evaluation if a lactulose breath test (LBT) had been performed prior to SBI. All patients were refractory to common IBS therapies. The response rate to the inclusion of SBI was calculated in three separate groups: dividing patients based on their LBT results (positive or negative), dividing patients by their IBS diagnosis (IBS-D or IBS-M) and grouping all patients together. Results: Analysis was carried out on 26 IBS-D/-M patients with LBT results. Two patients were lost to follow-up and were excluded from data analysis. The positive LBT group (N = 11) had a 73% (p = 0.117) positive response rate to SBI. The negative LBT group (N = 13) had a significant response rate of 77% (p = 0.040). If patients were divided by IBS diagnosis or grouped together, the response rate to SBI was similarly ranging from 69% - 88%. Adverse events leading to cessation of SBI occurred in 3 of 24 patients. Conclusion: SBI appeared to be a safe and effective nutritional moiety in refractory IBS-D and IBS-M patients. Larger, double-blind studies are needed.
Name: dc.source
Content: Open Journal of Gastroenterology
Name: dc.format
Content: text/html
Name: dc.publisher
Content: Scientific Research Publishing
Name: dc.date
Content: 2014-10-16
Name: dc.type
Content: Articles
Name: dc.identifier
Content: doi:10.4236/ojgas.2014.410047
Name: dc.language
Content: en
Name: prism.issnPrint
Content: 2163-9450
Name: prism.issnOnline
Content: 2163-9469
Name: prism.publicationName
Content: Open Journal of Gastroenterology
Name: prism.publicationDate
Content: 2014-10-16
Name: prism.volume
Content: 04
Name: prism.number
Content: 10
Name: prism.section
Content: Articles
Name: prism.startingPage
Content: 329
Name: prism.doi
Content: 10.4236/ojgas.2014.410047
Name: Author
Content: Scientific Research Publishing
Name: viewport
Content: width=974px
Name: DC.rights
Content: (c) 2015 by author(s) and Scientific Research Publishing Inc.

Server / Hosting

IP: 107.167.14.227
Latitude: 34.06
Longitude: -118.28
Country: United States
City: Los Angeles

Rname

ns30.worldnic.com
ns29.worldnic.com
p.webcom.ctmail.com

Target

namehost.WORLDNIC.com

HTTP Header Response

HTTP/1.1 301 Moved Permanently Server: Sun-ONE-Web-Server/6.1 Date: Wed, 05 Oct 2016 19:37:04 GMT Content-Length: 122 Content-Type: text/html Location: http://www.scirp.org/journal/PaperInformation.aspx?paperID=50770 X-Cache: MISS from s_sh11 Via: 1.1 s_sh11 (squid/3.5.20) Connection: keep-alive HTTP/1.1 200 OK Cache-Control: public, max-age=600 Content-Length: 78135 Content-Type: text/html; charset=utf-8 Expires: Wed, 05 Oct 2016 19:43:20 GMT Last-Modified: Wed, 05 Oct 2016 19:33:20 GMT Vary: * Server: Microsoft-IIS/8.5 X-AspNet-Version: 2.0.50727 Set-Cookie: ASP.NET_SessionId=w2x4ld3nw2bahfmqin5mz1bq; path=/; HttpOnly X-Powered-By: ASP.NET Date: Wed, 05 Oct 2016 19:33:19 GMT X-Cache: MISS from s_sh11 Via: 1.1 s_sh11 (squid/3.5.20) Connection: keep-alive